3-MeO-PCP: Difference between revisions
>Tracer m Added Category:Hallucinogen |
>Warms m added missing word 'loss.' |
||
Line 39: | Line 39: | ||
*'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]]. | *'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]]. | ||
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges. | *'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges. | ||
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control | *'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control loss. | ||
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses. | *'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses. | ||
*'''[[Effect::Appetite suppression]]''' | *'''[[Effect::Appetite suppression]]''' | ||
Line 120: | Line 120: | ||
{{#ask: [[Category:3-MeO-PCP]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:3-MeO-PCP]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml Erowid Experience Vaults: 3-MeO-PCP] | |||
*[https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml Erowid Experience Vaults: 3-MeO-PCP] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
Line 136: | Line 137: | ||
3-MeO-PCP has been reported to cause [[psychosis]], [[delusions]], and [[mania]] at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.<ref name="three">The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2</ref><ref name="two">The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity</ref><ref name="one">The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29</ref> In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.<ref name="six">Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26295489</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10 | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 | 23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675</ref><ref>https://www.erowid.org/experiences/exp.php?ID=103972 | NumbnDumb. "So Strong I'm Shocked: An Experience with 3-MeO-PCP (ID 103972)". Erowid.org. Jan 24, 2016. erowid.org/exp/103972</ref> | 3-MeO-PCP has been reported to cause [[psychosis]], [[delusions]], and [[mania]] at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.<ref name="three">The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2</ref><ref name="two">The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity</ref><ref name="one">The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29</ref> In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.<ref name="six">Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26295489</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10 | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 | 23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675</ref><ref>https://www.erowid.org/experiences/exp.php?ID=103972 | NumbnDumb. "So Strong I'm Shocked: An Experience with 3-MeO-PCP (ID 103972)". Erowid.org. Jan 24, 2016. erowid.org/exp/103972</ref> | ||
*Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects. | *Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects. | ||
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well. | *The recommended dosage range should not be exceeded as high doses can trigger these effects as well. | ||
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg. | *Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg. | ||
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose. | *[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose. | ||
Line 148: | Line 149: | ||
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as: | In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as: | ||
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes. | *'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes. | ||
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate. | *'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate. | ||
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination. | *'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination. | ||
Line 162: | Line 163: | ||
==Legal status== | ==Legal status== | ||
*'''Austria:''' 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | *'''Austria:''' 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | ||
*'''Brazil:''' As of May 17, 2018, 25C-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref> | *'''Brazil:''' As of May 17, 2018, 25C-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref> | ||
Line 171: | Line 173: | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
**[[Volumetric dosing]] | **[[Volumetric dosing]] | ||
Line 180: | Line 183: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/3-MeO-PCP 3-MeO-PCP (Wikipedia)] | *[https://en.wikipedia.org/wiki/3-MeO-PCP 3-MeO-PCP (Wikipedia)] | ||
*[https://erowid.org/chemicals/3-meo-pcp/ 3-MeO-PCP (Erowid Vault)] | *[https://erowid.org/chemicals/3-meo-pcp/ 3-MeO-PCP (Erowid Vault)] | ||
Line 185: | Line 189: | ||
===Discussion and Media=== | ===Discussion and Media=== | ||
*[http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2 The Big & Dandy 3-MeO-PCP Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2 The Big & Dandy 3-MeO-PCP Thread (Bluelight)] | ||
*[https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist (VICE)] | *[https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist (VICE)] | ||
==Literature== | ==Literature== | ||
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620 | |||
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620 | |||
==References== | ==References== |